HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS

单纯疱疹病毒异源结合疫苗

• 批准号: 6373837
• 负责人: Daniel Hill Zimmerman
• 金额: $ 38.51万
• 依托单位: CEL-SCI CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6373837
• 关键词: Herpesviridae vaccine; T lymphocyte; glycoproteins; guinea pigs; herpes simplex virus 1; immunity; immunoconjugates; laboratory mouse; ligands; peptides; synthetic vaccines; vaccine development; virus antigen; virus protein

The primary goal of this program is the development of L.E.A.P.S.(TM) heteroconjugate peptide vaccines against herpes simplex virus) to prevent or treat human infection. The heteroconjugate vaccines are constructed of peptides which contain defined T cell epitopes and peptides which are predicted to bind to T cells or antigen presenting cells. The T cell epitopes that are being used are from the ICP27, glycoprotein B, and glycoprotein D of HSV-1. Our Phase I studies proved the principle behind this new technology by showing that incorporation of a viral peptide epitope into a L.E.A.P.S. construct based vaccine can enhance and define the type of immune response which is elicited to promote the development of protective and not detrimental immune responses. A L.E.A.P.S. vaccine can then be formulation with LEAPS constructs assembled with adjuvants to produce defined immune responses to defined epitopes. The major goal of the Phase II studies will be to optimize the vaccine formulation with respect to L.E.A.P.S. peptide (or mixture), the adjuvant and other components to allow progression to human trials. In addition, we will study the mechanism of action by which the L.E.A.P.S. peptide potentiates the immune response. The HSV vaccines are also prototypes for the development of heteroconjugate vaccine to treat or prevent disease caused by other infectious agents. The ultimate goal of our study will be to develop sufficient data to allow progression to human trials. PROPOSED COMMERCIAL APPLICATION: Heteroconjugate peptide vaccines use proprietary new technology called L.E.A.P.S. (Ligand Epitope Antigen Presentation System) to provide treatment and/or prophlysis against herpes simplex virus (HSV) infection and disease. HSV is a common oral pathogen and sexually transmitted disease which also causes serious disease. An estimated 40 to 60 million Americans are infected with HSV with approximately 600,000 new cases occurring per year. The HSV vaccine will be prototypes for the development of heteroconjugate vaccines to treat or prevent disease by other infectious agents.

该计划的主要目标是开发L.E.A.P.S. (TM)针对单纯疱疹病毒的异源缀合肽疫苗）用于预防或治疗人感染。 异源缀合物疫苗由含有确定的T细胞表位的肽和预测与T细胞或抗原呈递细胞结合的肽构建。使用的T细胞表位来自HSV-1的ICP 27、糖蛋白B和糖蛋白D。我们的I期研究证明了这项新技术背后的原理，表明将病毒肽表位掺入L.E.A.P.S.基于构建体的疫苗可以增强和确定免疫应答的类型，所述免疫应答被引发以促进保护性而非有害的免疫应答的发展。L.E.A.P.S.然后可以用与佐剂组装的LEAPS构建体配制疫苗，以产生针对确定表位的确定免疫应答。II期研究的主要目标是针对L.E.A.P.S.优化疫苗配方。肽（或混合物）、佐剂和其它组分以允许进展到人体试验。 此外，我们将研究L.E.A.P.S.肽增强免疫应答。HSV疫苗也是开发用于治疗或预防由其他传染性因子引起的疾病的异源缀合物疫苗的原型。我们研究的最终目标将是开发足够的数据，以便进行人体试验。拟议的商业应用：异源结合肽疫苗使用称为L.E.A.P.S.的专有新技术。（配体表位抗原呈递系统）来提供针对单纯疱疹病毒（HSV）感染和疾病的治疗和/或预防。HSV是一种常见的口腔病原体和性传播疾病，也会导致严重的疾病。估计有4000万至6000万美国人感染HSV，每年约有60万新病例。HSV疫苗将成为开发用于治疗或预防由其他传染性病原体引起的疾病的异源缀合物疫苗的原型。